593 related articles for article (PubMed ID: 23095830)
1. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention.
Grisold W; Cavaletti G; Windebank AJ
Neuro Oncol; 2012 Sep; 14 Suppl 4(Suppl 4):iv45-54. PubMed ID: 23095830
[TBL] [Abstract][Full Text] [Related]
2. A randomised, placebo-controlled trial assessing the efficacy of an oral B group vitamin in preventing the development of chemotherapy-induced peripheral neuropathy (CIPN).
Schloss JM; Colosimo M; Airey C; Masci P; Linnane AW; Vitetta L
Support Care Cancer; 2017 Jan; 25(1):195-204. PubMed ID: 27612466
[TBL] [Abstract][Full Text] [Related]
3. Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: From pathogenesis to treatment.
Islam B; Lustberg M; Staff NP; Kolb N; Alberti P; Argyriou AA
J Peripher Nerv Syst; 2019 Oct; 24 Suppl 2():S63-S73. PubMed ID: 31647152
[TBL] [Abstract][Full Text] [Related]
4. Role for Drug Transporters in Chemotherapy-Induced Peripheral Neuropathy.
Stage TB; Hu S; Sparreboom A; Kroetz DL
Clin Transl Sci; 2021 Mar; 14(2):460-467. PubMed ID: 33142018
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy-induced neuropathy: A comprehensive survey.
Miltenburg NC; Boogerd W
Cancer Treat Rev; 2014 Aug; 40(7):872-82. PubMed ID: 24830939
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.
Argyriou AA; Bruna J; Marmiroli P; Cavaletti G
Crit Rev Oncol Hematol; 2012 Apr; 82(1):51-77. PubMed ID: 21908200
[TBL] [Abstract][Full Text] [Related]
8. [Chemotherapy-induced peripheral neuropathy].
Noguchi E; Maeda Y
Gan To Kagaku Ryoho; 2011 Nov; 38(11):1773-6. PubMed ID: 22083183
[TBL] [Abstract][Full Text] [Related]
9. Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.
Chan A; Hertz DL; Morales M; Adams EJ; Gordon S; Tan CJ; Staff NP; Kamath J; Oh J; Shinde S; Pon D; Dixit N; D'Olimpio J; Dumitrescu C; Gobbo M; Kober K; Mayo S; Pang L; Subbiah I; Beutler AS; Peters KB; Loprinzi C; Lustberg MB
Support Care Cancer; 2019 Oct; 27(10):3729-3737. PubMed ID: 31363906
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of Chemotherapy-Induced Peripheral Neuropathy.
Zajączkowska R; Kocot-Kępska M; Leppert W; Wrzosek A; Mika J; Wordliczek J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30909387
[TBL] [Abstract][Full Text] [Related]
11. Chemotherapy and peripheral neuropathy.
Li T; Mizrahi D; Goldstein D; Kiernan MC; Park SB
Neurol Sci; 2021 Oct; 42(10):4109-4121. PubMed ID: 34436727
[TBL] [Abstract][Full Text] [Related]
12. Modulation by Ozone Therapy of Oxidative Stress in Chemotherapy-Induced Peripheral Neuropathy: The Background for a Randomized Clinical Trial.
Clavo B; Martínez-Sánchez G; Rodríguez-Esparragón F; Rodríguez-Abreu D; Galván S; Aguiar-Bujanda D; Díaz-Garrido JA; Cañas S; Torres-Mata LB; Fabelo H; Téllez T; Santana-Rodríguez N; Fernández-Pérez L; Marrero-Callico G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802143
[TBL] [Abstract][Full Text] [Related]
13. Statistical identification of predictors for peripheral neuropathy associated with administration of bortezomib, taxanes, oxaliplatin or vincristine using ordered logistic regression analysis.
Kanbayashi Y; Hosokawa T; Okamoto K; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Taniwaki M
Anticancer Drugs; 2010 Oct; 21(9):877-81. PubMed ID: 20679888
[TBL] [Abstract][Full Text] [Related]
14. Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity.
Alberti P; Cavaletti G; Cornblath DR
Curr Opin Neurol; 2019 Oct; 32(5):676-683. PubMed ID: 31306214
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-induced peripheral neurotoxicity.
Cavaletti G; Marmiroli P
Expert Opin Drug Saf; 2004 Nov; 3(6):535-46. PubMed ID: 15500413
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced peripheral neuropathy-patient-reported outcomes compared with NCI-CTCAE grade.
Tan AC; McCrary JM; Park SB; Trinh T; Goldstein D
Support Care Cancer; 2019 Dec; 27(12):4771-4777. PubMed ID: 30972648
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy-induced neuropathy.
Windebank AJ; Grisold W
J Peripher Nerv Syst; 2008 Mar; 13(1):27-46. PubMed ID: 18346229
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.
Ibrahim EY; Ehrlich BE
Crit Rev Oncol Hematol; 2020 Jan; 145():102831. PubMed ID: 31783290
[TBL] [Abstract][Full Text] [Related]
19. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced peripheral neuropathy-part 2: focus on the prevention of oxaliplatin-induced neurotoxicity.
Sałat K
Pharmacol Rep; 2020 Jun; 72(3):508-527. PubMed ID: 32347537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
